Latest Orphan drugs Stories

( ) ( ) ( ) SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the upcoming presentations of data highlighting Nexavar® (sorafenib) tablets, Kyprolis(TM) (proposed trademark for carfilzomib) and regorafenib, a Bayer-owned compound for which Onyx will receive a royalty on global net sales. These presentations will take place at the 48th American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2012, in Chicago,...

INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from several molecules that make up its clinical oncology pipeline during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 1 - 5, 2012. Lilly Oncology has more than 30 molecules in early- and late-stage development to treat various types of cancer. The company remains committed to evaluating each of its molecules for biomarkers...

WASHINGTON, May 7, 2012 /PRNewswire-USNewswire/ -- A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP). In study results published online today in Blood, the Journal of the American Society of Hematology (ASH), investigators at Weill Cornell Medical...

Connie K. Ho for RedOrbit.com On Tuesday, April 17, researchers from the University of California, San Francisco (UCSF) presented results at the American Association of Neurological Surgeons (AANS) meeting in Miami, Florida that a new brain cancer vaccine tailored to individual subjects had been successful in its second clinical trial. The vaccine is for patients who suffer from recurrent glioblastoma multiforme, a type of cancer, and it has helped extend patients’ lives. The trial...

MONTREAL, April 17, 2012 /PRNewswire/ -The CML Society of Canada commends the Ontario government for the recent decision to add Sprycel (dasatinib) and Tasigna (nilotinib) to the list of CML (chronic myelogenous leukemia) treatments reimbursed in first line, giving patients newly diagnosed with CML more treatment options earlier.  As patient advocates for equal access to all available therapies, the CML Society of Canada feels it is important that governments are aware that it is...

A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4. "The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A....

BRUSSELS, February 29, 2012 /PRNewswire/ -- In the news release, "'Breathtaking' Campaign Launched to Raise Awareness of Deadly Lung Disease, Pulmonary Hypertension, on Rare Disease Day" issued on 28 Feb 2012 23:01 GMT, by Pulmonary Hypertension Association Europe and Bayer HealthCare over PR Newswire, we are advised by a representative of the company that a new link fits into the following passage of text: "Footage of the 'Breathtaking' campaign events will be available at the following...

BRUSSELS, February 28, 2012 /PRNewswire/ -- Events held across Europe to highlight little-known, life-threatening condition that takes breath away[1] A campaign has been launched today, on Rare Disease Day, to raise awareness of the little known but deadly disease, pulmonary hypertension (PH) and in particular, a rare form called pulmonary arterial hypertension (PAH). Events are taking place across Europe, with a key event in...

MALVERN, Pa., and ALLSCHWIL/BASEL, Switzerland, Feb. 23, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Actelion Pharmaceuticals Ltd. (SWX: ATLN.S) announced today that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX® (collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease. Under the terms of the...

SEATTLE, Feb. 17, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that Pixuvri(TM) (pixantrone dimaleate) has been granted a positive opinion for conditional approval from the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP"). Based on the CHMP's recommendation, CTI expects that a conditional marketing authorization for Pixuvri should be granted by the European Commission within the next few...